Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration

Retina

Volumn 29, Issue 2, 2009, Pages 133-148

  Shah, Gaurav K ^a   Sang, Delia N ^b   Hughes, Mark S ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DEXAMETHASONE; ENDOSTATIN; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VERTEPORFIN; APTAMER; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; PORPHYRIN; VASCULOTROPIN A;

ABRASION; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLINDNESS; BLOOD FLOW; BLOOD VESSEL OCCLUSION; BLURRED VISION; BREAST CANCER; CARDIOVASCULAR DISEASE; CAREGIVER; CATARACT; CELL PROLIFERATION; CHOROID; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTRAST SENSITIVITY; CORNEA ABRASION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE DISCOMFORT; EYE INFLAMMATION; EYE IRRITATION; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HEALTH CARE SYSTEM; HEART INFARCTION; HUMAN; HYPOTHESIS; INTRAOCULAR PRESSURE; IRRADIATION; KIDNEY CANCER; LUNG CANCER; MEDLINE; METASTASIS; OPEN STUDY; OPTICAL COHERENCE TOMOGRAPHY; OXIDATIVE STRESS; PATHOGENESIS; PATIENT MONITORING; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PHYSICIAN; PIGMENT EPITHELIUM; PILOT STUDY; PROSPECTIVE STUDY; RECURRENT DISEASE; REGISTER; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; RETREATMENT; RETROSPECTIVE STUDY; SHAM PROCEDURE; SIDE EFFECT; STROKE; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; THICKNESS; THREE DIMENSIONAL IMAGING; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UVEITIS; VISION; VISUAL ACUITY; VITREOUS BODY DETACHMENT; DRUG ANTAGONISM; DRUG COMBINATION; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 63249121270     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181960a28     Document Type: Article

References (113)

1. Rubin GS, Roche KB, Prasada-Rao P, Fried LP. Visual impairment and disability in older adults. Optom Vis Sci 1994;71:750 -760.
2. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol 1998;116:514-520.
3. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572.
4. Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2007;29:1850-1861.
5. Kent D, Sheridan C. Choroidal neovascularization: a wound healing perspective. Mol Vis 2003;9:747-755.
6. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122:598-614.
7. Gille J. Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor-and growth factor receptor-targeted approaches. Exp Derma-tol 2006;15:175-186.
8. Caprioni F, Fornarini G. Bevacizumab in the treatment of metastatic colorectal cancer. Future Oncol 2007;3:141-148.
9. Giaccone G. The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res 2007;13:1961-1970.
10. Mancuso A, Calabro F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 2006;58:231-241.
11. Han ES, Monk BJ. Bevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther 2007;7:1339-1345.
12. Taiwo BO. Antiretroviral treatment: current approach and future prospects. Afr J Med Med Sci 2006;35:S1-S11.
13. Sturmer M, Staszewski S, Doerr HW. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Antivir Ther 2007;12:695-703.
14. Weir MR. Risk-based classification of hypertension and the role of combination therapy. J Clin Hypertens (Greenwich) 2008;10:4-12.
15. Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens (Greenwich) 2008;10:20-26.
16. Pauleikhoff D. Neovascular age-related macular degeneration: natural history and treatment outcomes. Retina 2005;25: 1065-1084.
17. Macular Photocoagulation Study Group. Argon laser photo-coagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Arch Ophthalmol 1986;104: 694-701.
18. Macular Photocoagulation Study Group. Argon laser photo-coagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991;109: 1109-1114.
19. Macular Photocoagulation Study Group. Krypton laser pho-tocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1990;108:816-824.
20. Macular Photocoagulation Study Group. Laser photocoagu-lation of subfoveal neovascular lesions of age-related macu-lar degeneration. Updated findings from two clinical trials. Arch Ophthalmol 1993;111:1200-1209.
21. Macular Photocoagulation Study Group. Subfoveal neovas-cular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991;109:1242-1257.
22. Macular Photocoagulation Study Group. Laser photocoagu-lation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1232-1241.
23. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Arch Ophthalmol 1990;108:825-831.
24. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after laser photocoagulation for sub-foveal choroidal neovascularization of age-related macular degeneration. Arch Ophthalmol 1994;112:489-499.
25. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Arch Ophthalmol 1994;112:480-488.
26. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627-637.
27. Novack GD. Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration. Annu Rev Pharmacol Toxicol 2008;48:61-78.
28. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
29. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
30. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19: 361-372.
31. Brown DM. Lucentis: PIER data. Retinal Physician 2006 Symposium, Atlantis, Paradise Island, Bahamas, May 31- June 3, 2006.
32. Azad R, Chandra P, Gupta R. The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol 2007; 55:441- 443.
33. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study Year 1. Am J Ophthalmol 2008;145:239-248.
34. Slakter JS, DENALI Study Group. SUMMIT: combination therapy with verteporfin PDT and ranibizumab for subfoveal choroidal neovascularization due to AMD. Invest Ophthalmol Vis Sci 2007;48:E-Abstract 1817.
35. Kaiser PK. Verteporfin therapy in combination with triamcinolone: published studies investigating a potential synergistic effect. Curr Med Res Opin 2005;21:705-713.
36. Kaiser PK. Steroids for choroidal neovascularization. Am J Ophthalmol 2005;139:533-535.
37. Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol 1999;117:1329-1345.
38. Azab M, Boyer DS, Bressler NM, et al; Visudyne In Minimally Classic CNV (VIM) Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-457.
39. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994;101:1953-1961.
40. Treatment of Age-related macular degeneration with Photo-dynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001;119:198-207.
41. Verteporfin in Photodynamic therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic therapy Report 2. Am J Ophthalmol 2001;131: 541-560.
42. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133-140.
43. Gelisken F, Lafaut BA, Inhoffen W, Voelker M, Grisanti S, Bartz-Schmidt KU. Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy. Br J Ophthalmol 2004;88:207-211.
44. Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002; 240:748-757.
45. Kaiser PK. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension - TAP Report No. 8. Graefes Arch Clin Exp Ophthalmol 2006;244:1132- 1142.
46. Azab M, Benchaboune M, Blinder KJ, et al; Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: treatment of age-related macular degeneration with photodynamic therapy and verteporfin in photodynamic therapy study report No. 4. Retina 2004;24:1-12.
47. Bandello F, Blinder K, Bressler NM; VIP Report No. 5 Writing Committee. Verteporfin in photodynamic therapy: report No. 5. Ophthalmology 2004;111:2144.
48. Arnold JJ, Blinder KJ, Bressler NM, et al. Acute severe visual acuity decrease after photodynamic therapy with verte-porfin: case reports from randomized clinical trials - TAP and VIP report no. 3. Am J Ophthalmol 2004;137:683-696.
49. Schnurrbusch UE, Jochmann C, Einbock W, Wolf S. Complications after photodynamic therapy. Arch Ophthalmol 2005;123:1347-1350.
50. Bandi N, Kompella UB. Budesonide reduces vascular endo-thelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur J Pharmacol 2001;425:109-116.
51. Folkman J, Ingber DE. Angiostatic steroids. Method of discovery and mechanism of action Ann Surg 1987;206:374- 383.
52. Tatar O, Shinoda K, Kaiserling E, et al. Early effects of triamcinolone on vascular endothelial growth factor and endostatin in human choroidal neovascularization. Arch Ophthalmol 2008;126:193-199.
53. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of tri-amcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304.
54. Tsuchiya D, Yamamoto T, Yamashita H. Combined therapy of photodynamic therapy with verteporfin and juxtascleral injection of triamcinolone acetonide for age-related macular degeneration. Invest Ophthalmol Vis Sci 2007;48:4547.
55. Sacu S, Varga A, Weigert G, et al. Comparison of reduced fluence versus standard fluence verteporfin therapy in combination with intravitreal triamcinolone acetonide: a prospective, randomized, controlled clinical trial. Invest Ophthalmol Vis Sci 2007;48:1831.
56. Jarzabek J, Pilli S, Mathapati D, et al. Role of timing for intravitreal triamcinolone injection following PDT for classic subfoveal choroidal neovascularization secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2007; 48:1446.
57. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy and triamcinolone acetonide: convergent modes of action for treatment of neovascular age-related macular degeneration. Eur J Ophthalmol 2006;16:824-834.
58. Gillies MC, Kuzniarz M, Craig J, Ball M, Wei L, Simpson JM. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005;112:139-143.
59. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-340.
60. Michels S, Schmidt-Erfurth U, Rosenfeld PJ. Promising new treatments for neovascular age-related macular degeneration. Expert Opin Investig Drugs 2006;15:779 -793.
61. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72:638-645.
62. Grunwald JE, Metelitsina TI, Dupont JC, Ying GS, Maguire MG. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005; 46:1033-1038.
63. Yoshida S, Yoshida A, Ishibashi T. Induction of IL-8, MCP-1, and bFGF by TNF-alpha in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation. Graefes Arch Clin Exp Ophthalmol 2004;242: 409-413.
64. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
65. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:642-644.
66. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-870.
67. Michels S, Rosenfeld PJ. Treatment of neovascular agerelated macular degeneration with Ranibizumab/Lucentis. Klin Monatsbl Augenheilkd 2005;222:480-484.
68. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
69. Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging 2007;24:643-662.
70. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neo- vascular age-related macular degeneration. Retina 2006;26: 495-511.
71. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neo-vascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
72. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bev-acizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27:439-444.
73. Aisenbrey S, Ziemssen F, Volker M, et al. Intravitreal bev-acizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:941-948.
74. Peters S, Julien S, Heiduschka P, et al. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 2007;91:827- 831.
75. Volcker M, Peters S, Inhoffen W, Ziemssen F. Early antiexudative response - OCT monitoring after intravitreal bevacizumab injection. Ophthalmologe 2006;103:476-483.
76. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
77. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related mac-ular degeneration. Am J Ophthalmol 2006;142:1-9.
78. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:1868-1875.
79. Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis 2007; 10:141-148.
80. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-1295.
81. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of antivascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168:2036- 2053.
82. Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26: 988-993.
83. Hughes MS, Sang DN. Reduced-duration photodynamic therapy (PDT) combined with dexamethasone and ranibizumab intravitreal injection in the treatment of exudative age-related macular degeneration. Poster presented at American Society of Retina Specialists; 2007.
84. Hughes MS, Sang DN. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2006;37:446-454.
85. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145:879-882.
86. Tan JS, Wang JJ, Liew G, et al. Age-related macular degen- eration and mortality from cardiovascular disease or stroke. Br J Ophthalmol 2008;92:509-512.
87. Gillies MC, Wong TY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007;356:748- 749.
88. Boyer DS. SAILOR Safety outcomes at one year: does ranibizumab increase the risk of thromboembolic events? Angiogenesis Meeting The Ritz-Carlton, Key Biscayne, FL; 2008.
89. Alexander SL, Linde-Zwirble WT, Werther W, et al. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology 2007;114:2174-2178.
90. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-1028.
91. Emerson MV, Lauer AK. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs 2007;21:245-257.
92. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67.
93. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2004;242:91-101.
94. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-1542.
95. Lanzetta P; FOCUS Study Group. Combination intravitreal ranibizumab 0.5mg and verteporfin PDT versus verteporfin PDT alone in the FOCUS study of neovascular age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci 2007;48:E-Abstract 2869.
96. Wolf S; PROTECT Study Group. Nine month exploratory endpoint results from an open-label, multicenter, phase II study of same-day verteporfin and ranibizumab 0.5 mg (PROTECT Study), as measured using optical coherence tomography (OCT), fundus photography and fluorescein angiography (FA). Invest Ophthalmol Vis Sci 2007;48:E-Abstract 2871.
97. Holz FG; PROTECT Study Group. Nine month safety and efficacy results from an open-label, multicenter, phase II study of same-day verteporfin and ranibizumab 0.5 mg (PROTECT Study). Invest Ophthalmol Vis Sci 2007;48:E-Abstract 4566.
98. Merrill PT, Civantos J, MacCumber M, Ho T. Combination lucentis and ocular photodynamic therapy with visudyne, with evaluation-based retreatments: CLOVER. Vail, CO: Vail Vitrectomy; 2007.
99. Kiss CG, Wagner J, Simader C, et al. Effect of photodynamic therapy (PDT) and ranibizumab on vascular anatomy and retinal function in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2007;48:E-Abstract 4544.
100. Romero RM, Monares G, De la Luz JC, et al. Randomized, double blind, controlled study with verteporfin photodynamic therapy and intravitreal triamcinolone (IVTA) vs triple theraphy with verteporfin photodynamic therapy, intravitreal triamcino-lone and intravitreal ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci 2007; 48:E-Abstract 72.
101. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GOH. Influence of pho- todynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44: 4473-4480.
102. Tatar O, Adam A, Shinoda K, et al. Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration. Retina 2007;27:713-723.
103. QLT Inc. Reduced fluence visudyne-anti-VEGF-dexamethasone in combination for AMD lesions (RADICAL). QLT Inc.; 2007. Available at http://www.qltinc.com/ Qltinc/main/ mainpages.cfm?InternetpageID=340.
104. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-1185.
105. Connolly BP, Rose SJ, Guillet E. Long term results of combination therapy for exudative age related macular degeneration using intraocular bevacizumab and photodynamic therapy with Visudyne: a consecutive case series. Invest Ophthalmol Vis Sci 2007;48:4555.
106. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 2007; 245:1273-1280.
107. Ladewig MS, Karl SE, Hamelmann V, et al. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2008;246:17-25.
108. Ahmadieh H, Taei R, Soheilian M, et al. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol 2007;7:10.
109. Banker AS, Sushil Kumar R. Triple combination therapy (photodynamic therapy with intravitreal bevacizumab and subtenon triamcinolone acetonide) for choroidal neovascularization: one year results. Indian Ophthalmol. Conference, 2008; paper 82[FP0052]:221.
110. Tolentino MJ. Verteporfin therapy and bevacizumab for wet AMD: the visudyne patient registry. American Academy of Ophthalmology (AAO) Annual Meeting; New Orleans, LA, November 10-13, 2007.
111. Hooper PL, Sheidow TG; VACT Study Group. Visudyne Anti-VEGF Combination Therapy (VACT): a multicentred, retrospective clinical practice review of combination therapy in AMD. Invest Ophthalmol Vis Sci 2007;48:4537.
112. Drexler W, Fujimoto JG. State-of-the-art retinal optical coherence tomography. Prog Retin Eye Res 2008;27:45-88.
113. van Velthoven ME, Faber DJ, Verbraak FD, et al. Recent developments in optical coherence tomography for imaging the retina. Prog Retin Eye Res 2007;26:57-77.